Physician profile
Ellen Pacia
NPI 1801880851
$13,462.05
in general payments reported to CMS, 2019-2025
41 companies · $2,480 in 2025
The $2,480 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,648 · 2020: $1,436 · 2021: $1,484 · 2022: $2,225 · 2023: $1,786 · 2024: $2,404 · 2025: $2,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,635 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,635.37 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,775.66 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,721.49 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $1,097.31 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $964.56 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Genzyme Corporation | $913.19 | 2019-2025 | |
| Grifols USA, LLC | $802.22 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $671.91 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $534.07 | 2020-2025 | Glassia, Hyqvia |
| Amgen INC. | $388.92 | 2022-2025 | Tezspire, Tavneos |
| Axsome Therapeutics, INC. | $347.82 | 2022-2024 | Sunosi |
| Merck Sharp & Dohme LLC | $285.54 | 2019-2025 | Winrevair |
| Genentech USA, INC. | $241.84 | 2019-2024 | Xolair |
| Mylan Specialty L.P. | $234.77 | 2023-2024 | Yupelri |
| Harmony Biosciences LLC | $222.20 | 2020-2024 | Wakix |
| United Therapeutics Corporation | $218.63 | 2021-2025 | Tyvaso, Tyvaso |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $205.61 | 2020-2025 | Arikayce, Brinsupri |
| Jazz Pharmaceuticals INC. | $201.02 | 2019-2024 | |
| Inspire Medical Systems, INC. | $192.67 | 2023-2025 | Inspire |
| Philips North America LLC | $187.11 | 2020-2025 | Vest Therapy Und |
| Bayer Healthcare Pharmaceuticals INC. | $177.82 | 2019-2025 | |
| Viatris Specialty LLC | $152.63 | 2025 | Yupelri |
| Baxter Healthcare | $149.98 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Lilly USA, LLC | $136.20 | 2025 | Zepbound, Mounjaro |
| Pfizer INC. | $77.02 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $69.13 | 2020-2025 | Acthar |
| Pulmonx Corporation | $58.86 | 2021-2024 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Teva Pharmaceuticals USA, INC. | $56.30 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $50.61 | 2022 | |
| Gilead Sciences, INC. | $48.37 | 2021 | |
| Mallinckrodt Enterprises LLC | $48.33 | 2019 | |
| Verona Pharma, INC. | $41.16 | 2025 | Ohtuvayre |
| Kaleo, INC. | $26.42 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $23.06 | 2022 | |
| Breathe Technologies, INC. | $22.71 | 2019 | |
| Pharming Healthcare, INC. | $20.83 | 2023 | Ruconest |
| Shire North American Group INC | $18.52 | 2019 | |
| La Jolla Pharmaceutical Company | $16.92 | 2025 | Giapreza |
| Advanced Respiratory, INC | $16.68 | 2019 | |
| Covis Pharma Gmbh | $15.35 | 2022 | |
| Vifor Pharma, INC. | $14.98 | 2025 | Zemaira |
| Circassia INC. | $13.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Pacia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.